JPMorgan Chase & Co. Reiterates Underweight Rating for GSK (LON:GSK)

JPMorgan Chase & Co. reissued their underweight rating on shares of GSK (LON:GSK) in a report issued on Wednesday, Marketbeat reports.

Other equities analysts have also issued research reports about the stock. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a GBX 1,850 ($23.35) price target on shares of GSK in a research report on Tuesday, September 3rd. Shore Capital reissued a “buy” rating on shares of GSK in a research report on Wednesday, August 28th. Finally, Berenberg Bank decreased their price target on shares of GSK from GBX 1,820 ($22.97) to GBX 1,600 ($20.19) and set a “buy” rating for the company in a research note on Friday, November 29th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, GSK presently has an average rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($22.79).

GSK Stock Down 0.3 %

GSK stock opened at GBX 1,329.50 ($16.78) on Wednesday. The stock has a market cap of £54.24 billion, a P/E ratio of 1,179.54, a P/E/G ratio of 1.24 and a beta of 0.31. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 123.04. The stock’s fifty day simple moving average is GBX 1,407.02 and its two-hundred day simple moving average is GBX 1,527.55. GSK has a 1-year low of GBX 1,282.50 ($16.19) and a 1-year high of GBX 1,823.50 ($23.02).

GSK Dividend Announcement

The business also recently declared a dividend, which will be paid on Thursday, January 9th. Shareholders of record on Thursday, November 14th will be paid a GBX 15 ($0.19) dividend. The ex-dividend date of this dividend is Thursday, November 14th. This represents a yield of 1.03%. GSK’s dividend payout ratio (DPR) is currently 5,309.73%.

Insider Buying and Selling at GSK

In other GSK news, insider Jonathan Symonds purchased 7,150 shares of GSK stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of GBX 1,394 ($17.59) per share, for a total transaction of £99,671 ($125,799.57). Also, insider Elizabeth (Liz) McKee Anderson acquired 446 shares of the company’s stock in a transaction on Monday, September 23rd. The stock was acquired at an average price of GBX 2,051 ($25.89) per share, with a total value of £9,147.46 ($11,545.45). Over the last 90 days, insiders purchased 7,604 shares of company stock worth $10,893,038. 1.61% of the stock is currently owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.